|
Age, yrs
|
|
Median age (range)
|
55 (39–77)
|
|
≤ 55
|
12 (54.5)
|
|
> 55
|
10 (45.5)
|
|
Primary tumor location
|
|
Ovary
|
21 (95.5)
|
|
Fallopian tube
|
1 (4.5)
|
|
International FIGO stage
|
|
II
|
2 (9.1)
|
|
III
|
11 (50.0)
|
|
IV
|
8 (36.4)
|
|
Unknown
|
1 (4.5)
|
|
Histological type
|
|
High-grade serous
|
19 (86.4)
|
|
Low-grade serous
|
1 (4.5)
|
|
Other
|
1 (4.5)
|
|
Unknown
|
1 (4.5)
|
|
Family history of cancer
|
|
Yes
|
9 (40.9)
|
|
No
|
13 (59.1)
|
|
ECOG
|
|
0
|
8 (36.4)
|
|
1
|
13 (59.1)
|
|
2
|
1 (4.5)
|
|
Baseline body weight
|
|
≥ 77 kg
|
0 (0)
|
|
< 77 kg
|
22 (100)
|
|
Platelet count
|
|
≥ 150 × 109/L
|
12 (54.5)
|
|
< 150 × 109/L
|
10 (45.5)
|
|
HRD status
|
|
HRD-positive
|
6 (27.3)
|
|
BRCA-mutated
|
1 (4.5)
|
|
BRCA-wild type or BRCA-unknown and HRD-positive
|
5 (22.7)
|
|
HRD-negative
|
8 (36.4)
|
|
HRD unknown
|
8 (36.4)
|
|
Prior lines of chemotherapy
|
|
≤ 1
|
12 (54.5)
|
|
> 1
|
10 (45.5)
|
|
Platinum status
|
|
Platinum-sensitive
|
5 (22.7)
|
|
Platinum-resistant
|
5 (22.7)
|
|
Unknown
|
12 (54.5)
|
|
Categories of therapy
|
|
First-line maintenance therapy
|
6 (27.3)
|
|
Exploratory therapy
|
16 (72.7)
|
|
Exploratory second-line maintenance therapy
|
1 (4.5)
|
|
Exploratory front-line therapy
|
6 (27.3)
|
|
Exploratory multi-line therapy
|
9 (40.9)
|
|
NACT+IDS
|
|
Yes
|
7 (31.8)
|
|
No
|
15 (68.2)
|
|
Primary debulking surgery
|
|
Yes
|
12 (54.5)
|
|
No
|
10 (45.5)
|
|
Secondary cytoreductive surgery
|
|
Yes
|
3 (13.6)
|
|
No
|
19 (86.4)
|
|
Combination with other agents
|
|
Yes
|
4 (18.2)
|
|
No
|
18 (81.8)
|
